The extension of the sequencing to intergenic regions allowed evaluation of the burden of putative driver mutations in noncoding regions: on the pan‐cancer database, 13% of all mutations were represented by driver point‐mutation events in an intergenic region, with 25% of all PCAWG cancers analysed bearing at least one, one‐third of which occurred in the TERT promoter, confirming its role in cancer [73, 74, 75, 76, 77, 78, 79]. This evidence concerns the gene TERT and cancer.